SecBot SecBot
PRESS-RELEASE ·Filed Mar 1, 2026

CLDX

Celldex Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Investors should monitor enrollment progress in the Phase 3 EMBARQ trial and upcoming interim or topline results, which could serve as major catalysts. The retreatment data de-risk development by supporting flexible dosing, potentially improving compliance and commercial adoption.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$30.00
T+0 close · Mar 1, 2026 · via day close
Latest settled
+2.83%
T+60 · $30.85
Vs SPY
−6.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $30.00entry
  2. T+1 · 9mo ago −3.53%α −2.62% · $28.94
  3. T+5 · 8mo ago +2.43%α +3.64% · $30.73
  4. T+20 · 8mo ago −1.73%α +6.20% · $29.48
  5. T+60 · 6mo ago +2.83%α −6.49% · $30.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celldex Therapeutics presented positive Phase 2 open-label extension data for barzolvolimab in ColdU and SD, showing that retreatment leads to rapid and high rates of complete response, supporting the potential for intermittent, real-world treatment. The data reinforce the drug's durable efficacy and favorable safety profile, with 62% (ColdU) and 60% (SD) achieving complete response upon retreatment. A global Phase 3 trial is ongoing.

Key Facts

  • Barzolvolimab retreatment achieved 62% complete response in ColdU and 60% in SD at Week 20 of the OLE, consistent with initial treatment efficacy.
  • Among patients who achieved complete response initially, 82% (ColdU) and 86% (SD) achieved it again upon retreatment.
  • Rapid improvement in urticaria control and symptom thresholds observed upon retreatment.
  • Barzolvolimab targets mast cells via KIT receptor inhibition, a novel mechanism for chronic inducible urticarias.
  • Global Phase 3 trial (EMBARQ-ColdU and SD, NCT07266402) is enrolling, initiated in late 2025.

Financial Impact

High potential commercial value; addresses an underserved market with no approved therapies beyond antihistamines. Phase 3 advancement increases probability of regulatory approval and future revenue generation.

pipeline_valuerevenue_potentialr_d_expensemarket_cap

Risk Factors

  • Phase 3 trial may not replicate Phase 2 results.
  • Regulatory approval not guaranteed despite promising data.
  • Competition could emerge if other mast cell or biologic therapies advance in urticaria.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3246936

Track record

21 reports on CLDX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 3 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.83 −0.48% settles Feb 12
  2. Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.83 −3.48% settles Feb 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.83 −3.48% settles Feb 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.83 −2.96% settles Feb 1
  5. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.83 −5.26% settles Jan 4
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.83 −13.97% settles Dec 16
  7. Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.83 −13.97% settles Dec 16
  8. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.83 −13.97% settles Dec 16
  9. Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.83 +10.24% ▼ −18.62% −18.22% vs SPY
  10. Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.83 −10.24% ▲ +18.62% +18.22% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (12h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 1, 2026